{
    "Clinical Trial ID": "NCT00127205",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I Zoledronate",
        "  Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.",
        "  zoledronic acid: Given IV",
        "INTERVENTION 2: ",
        "  Arm II Clodronate",
        "  Patients receive oral clodronate once daily for 35 months.",
        "  clodronate disodium: Given orally"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed primary adenocarcinoma of the breast",
        "  Stage I-III disease",
        "  No evidence of metastatic disease",
        "  Must have undergone lumpectomy or total mastectomy for primary disease within the past 12 weeks, or have completed chemotherapy within the past 8 weeks",
        "  Axillary evaluation per institutional standards",
        "  Currently receiving or planning to receive standard adjuvant systemic therapy comprising chemotherapy, hormonal therapy, or combined chemotherapy/hormonal therapy for breast cancer",
        "  Patients who are at low risk for disease recurrence and for whom adjuvant systemic therapy will not be prescribed are not eligible",
        "  Patients who receive biologic agents only or local radiotherapy only (without chemotherapy and/or hormone therapy) are not eligible",
        "  Additional therapies are allowed including radiotherapy and biologic agents (e.g., trastuzumab [Herceptin^\u00ae], bevacizumab, or hematopoietic growth factors)",
        "  Neoadjuvant therapy or hormonal therapy alone is allowed provided study entry occurs  12 weeks after completion of surgery",
        "  Patients with skeletal pain are eligible provided bone scan and/or roentgenological exam are negative for metastatic disease",
        "  Suspicious findings must be confirmed as benign by x-ray, MRI, or biopsy",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  18 and over",
        "  Sex",
        "  Female",
        "  Menopausal status",
        "  Not specified",
        "  Performance status",
        "  Zubrod 0-2",
        "  Life expectancy",
        "  Not specified",
        "  Hematopoietic",
        "  Not specified",
        "  Hepatic",
        "  Not specified",
        "  Renal",
        "  Creatinine  2 times upper limit of normal",
        "  Creatinine clearance  30 mL/min",
        "  No renal failure",
        "  Other",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  No history of esophageal stricture or motility disorders",
        "  Gastroesophageal reflux disorder allowed",
        "  No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  Prior or concurrent hematopoietic growth factors allowed",
        "  HER-2-targeted therapies allowed",
        "  Antiangiogenics allowed",
        "  Chemotherapy",
        "  See Disease Characteristics",
        "  Endocrine therapy",
        "  See Disease Characteristics",
        "  Radiotherapy",
        "  Concurrent radiotherapy to the breast, chest wall, or lymph node group allowed at the discretion of the treating physician",
        "  Surgery",
        "  See Disease Characteristics",
        "  Other",
        "  Prior neoadjuvant therapy allowed",
        "  Prior bisphosphonates for bone density allowed",
        "  No other concurrent bisphosphonates as adjuvant therapy or for treatment of osteoporosis",
        "  No concurrent enrollment in clinical trials with bone density as an endpoint",
        "  Concurrent enrollment on any other locoregional or systemic therapy breast cancer study (including cooperative group studies) allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Disease-free Survival",
        "  Time from date of registration to date of first observation of recurrence or death due to any cause. Patients last known to be alive who have not experienced recurrence of disease are censored at their last contact date. The outcome for the disease-free survival will be presented as 5 year survival rate.",
        "  Time frame: Disease assessments are completed every 6 months for 5 years then annually for 5 years or until death or recurrence",
        "Results 1: ",
        "  Arm/Group Title: Arm I Zoledronate",
        "  Arm/Group Description: Patients receive zoledronate IV over 15 minutes once a month for 6 months and then once every 3 months for 2.5 years.",
        "  zoledronic acid: Given IV",
        "  Overall Number of Participants Analyzed: 2231",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of analyzed participants  88        (87 to 90)",
        "Results 2: ",
        "  Arm/Group Title: Arm II Clodronate",
        "  Arm/Group Description: Patients receive oral clodronate once daily for 35 months.",
        "  clodronate disodium: Given orally",
        "  Overall Number of Participants Analyzed: 2235",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of analyzed participants  88        (86 to 89)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 21/2125 (0.99%)",
        "  Febrile neutropenia 0/2125 (0.00%)",
        "  Hemoglobin 0/2125 (0.00%)",
        "  Cardiac General-Other 0/2125 (0.00%)",
        "  Cardiac-ischemia/infarction 1/2125 (0.05%)",
        "  Conduction abnorm/AV block - Sick sinus syndrome 0/2125 (0.00%)",
        "  Left ventricular diastolic dysfunction 0/2125 (0.00%)",
        "  Left ventricular systolic dysfunction 0/2125 (0.00%)",
        "  Pain - Cardiac/heart 0/2125 (0.00%)",
        "Adverse Events 2:",
        "  Total: 190/2186 (8.69%)",
        "  Febrile neutropenia 3/2186 (0.14%)",
        "  Hemoglobin 3/2186 (0.14%)",
        "  Cardiac General-Other 2/2186 (0.09%)",
        "  Cardiac-ischemia/infarction 1/2186 (0.05%)",
        "  Conduction abnorm/AV block - Sick sinus syndrome 1/2186 (0.05%)",
        "  Left ventricular diastolic dysfunction 3/2186 (0.14%)",
        "  Left ventricular systolic dysfunction 1/2186 (0.05%)",
        "  Pain - Cardiac/heart 3/2186 (0.14%)"
    ]
}